(Washington, D.C.) — As drugstore lobbyists descend on Albany today, it is important to highlight how pharmacy benefit managers (PBMs) advocate for consumers and health plan sponsors in the fight to keep prescription drugs accessible and affordable. It is equally
(Washington, D.C.) — The Pharmaceutical Care Management Association released the following statement on the Pennsylvania Auditor General’s report, “Bringing Transparency & Accountability to Drug Pricing:” “The Pennsylvania Auditor General has released yet another biased report on pharmacy benefit managers (PBMs).
The Medicare Prescription Drug Rebate Rule PCMA Urges Congress to Permanently Repeal Rebate Rule This Year The Medicare Part D prescription drug benefit provides our nation’s seniors with affordable drug coverage, which is more important now than ever. The rebate
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Health and Human Services Office of Inspector General’s proposed rule on prescription drug rebates in Medicare: “While we are reviewing the proposed
(Washington, D.C.) — The Pennsylvania Auditor General’s report on Medicaid and pharmacy benefit managers (PBMs) is undermined by failing to note a simple, but key critical element: PBMs are reducing prescription drug costs and increasing access to needed treatments for
(Washington, D.C.) — As the Administration considers modifying price concessions for prescription drugs in Medicare and federal programs, the Pharmaceutical Care Management Association (PCMA) is releasing new data, “Reconsidering Drug Prices, Rebates, and PBMs,” showing drug manufacturers alone set prices –
The Visante study highlights top selling Medicare Part D brand-name drugs with steady price increases and no change in rebate levels over a five-year period from 2012 to 2017. In addition, the study analyzes a number of Medicare Part B
(Washington, D.C.) — Today, the U.S. House of Representatives passed a legislative package, SUPPORT for Patients and Communities Act (H.R. 6), which requires electronic prescribing (e-prescribing) of controlled substances in Medicare. This is an important step in the fight against America’s
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a Medicare Part D report released today by the Office of Inspector (OIG), U.S. Department of Health and Human Services (HHS): “This report finally debunks the myth
©2024 PCMA. All Rights Reserved.
